SCHEMBL257542

SCHEMBL257542

Cc1ccc(-c2c(C)nn3c(-c4cccc(C)c4)cc(Cl)nc23)cc1

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.55
MAPT P10636 10/20 0.53
MAPK1 P28482 1/20 0.48
NPC1 O15118 3/20 0.45
NPSR1 Q6W5P4 1/20 0.45
KMT2A Q03164 4/20 0.45
ALDH1A1 P00352 3/20 0.45
MEN1 O00255 2/20 0.45
KDM4E B2RXH2 3/20 0.44
TDP1 Q9NUW8 1/20 0.42
RAB9A P51151 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
HTT P42858 2/20 0.42
LMNA P02545 2/20 0.42
HPGD P15428 2/20 0.42
HCRTR1 O43613 1/20 0.42
POLB P06746 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15042157 0.90 TP53 (0.67) TP53MAPTMAPK1NPC1NPSR1
SCHEMBL10072008 0.89 TP53 (0.52) TP53MAPTMAPK1NPC1NPSR1
SCHEMBL257404 0.87 MAPT (0.59) TP53MAPTMAPK1NPSR1ALDH1A1
SCHEMBL257701 0.86 TP53 (0.49) TP53MAPTMAPK1NPC1NPSR1
SCHEMBL256922 0.85 TP53 (0.65) TP53MAPTMAPK1NPC1NPSR1
SCHEMBL257382 0.84 TP53 (0.53) TP53MAPTMAPK1NPC1NPSR1
SCHEMBL257519 0.82 MAPT (0.40) TP53MAPTMAPK1NPC1NPSR1
SCHEMBL15020632 0.82 TP53 (0.79) TP53MAPTMAPK1NPC1NPSR1
SCHEMBL15121512 0.80 TP53 (0.45) TP53MAPTMAPK1NPC1NPSR1
SCHEMBL257698 0.78 MAPT (0.78) TP53MAPTMAPK1NPC1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8975264-B2 Compound acting as a cannabinoid receptor-1 inhibitor AMOREPACIFIC CORPORATION (KR) 2015-03-10 US disclosed
US-8975264-B2 Compound acting as a cannabinoid receptor-1 inhibitor AMOREPACIFIC CORPORATION (KR) 2015-03-10 US disclosed
US-8975264-B2 Compound acting as a cannabinoid receptor-1 inhibitor AMOREPACIFIC CORPORATION (KR) 2015-03-10 US disclosed
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR AMOREPACIFIC CORPORATION (KR) 2013-06-20 US disclosed
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR AMOREPACIFIC CORPORATION (KR) 2013-06-20 US disclosed
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR AMOREPACIFIC CORPORATION (KR) 2013-06-20 US disclosed
WO-2012030170-A2 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR (주)아모레퍼시픽 (KR) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR CNR1, CNR2, GPR18 TP53 4550/4885MAPT 2617/4885MAPK1 519/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.